Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2009

View Archived Issues

GW-3965 improves cognition in impaired mice

Tapentadol extended release shows efficacy and safety in phase III study of chronic pain

Phase I results for IVN-201 for cat dander allergy announced by ImVisioN

Vardenafil improves continence after prostatectomy; LUTS in benign prostatic hyperplasia patients

Shire voluntarily recalls Daytrana transdermal patch due to release liner defect

FDA approves Lexapro for major depressive disorder in adolescents

SkyePharma files NDA for Flutiform with the FDA

Merck Frosst Canada presents novel renin inhibitors

Allergan reports novel pyrrole compounds for the treatment of glaucoma

Clinical trial results for MB-07803 in type 2 diabetes reported by Metabasis

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

Novel clinical candidate for type 2 diabetes treatment described by Amgen

Novel histamine H3 receptor antagonist presented by Pfizer

Injection of adenovirus expressing SkM1 demonstrates antiarrhythmic activity

Micromet initiates phase II adecatumumab trial in colorectal cancer patients

Nereus Pharmaceuticals has begun a phase II trial of NPI-2358 in NSCLC

Transition initiates phase Ib TT-223/GLP-1 analogue study in type 2 diabetes

CHMP recommends marketing authorization for Astellas' Modigraf in transplant rejection

Oryzon acquires Crystax

NMRC submits revised IND to FDA to conduct RESUS clinical trial of Biopure's Hemopure

FDA approves Symbyax for treatment-resistant depression

Exalgo extended-release meets primary efficacy endpoint in phase III trial

Torii to launch Remitch in Japan for pruritus in hemodialysis

Vertex Pharmaceuticals claims novel protein kinase inhibitors

Roche presents novel pyrrolodine aryl-ether compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...